Cvs Health Stock Earnings Reports

CVS Health reported a strong start to 2026 with broad-based revenue growth and margin improvement, prompting management to raise full-year adjusted EPS guidance to $7.30–$7.50 (from $7.00–$7.20). Q1 highlights include adjusted operating income of ~$5.2 billion, adjusted EPS of $2.57, more than $100 billion of revenue (+6% YoY), and operating cash flow of ~$4.2 billion. Aetna (Health Care Benefits) showed material improvement—driving ~ $1 billion YOY AOI improvement—with an 84.6% medical benefit ratio in Q1 and continued focus on returning Medicare Advantage to target margins by 2028. Health Services (Caremark/PBM) revenue rose on drug mix and inflation, though AOI was down modestly due to client price improvements and timing; management noted rebate-guarantee execution largely in line with expectations. Pharmacy & Consumer Wellness delivered stable revenue and same-store growth (+3%); margins were pressured by regulatory price reductions and generic introductions but benefited from higher prescription volumes and retail script share gains. Strategic initiatives emphasized: driving affordability (insulin access at $25/month, excluding branded STELARA for biosimilar substitution effective July 1, 2026), prior-authorization standardization (Aetna has 88% of procedures standardized), accelerated AI/technology investment (launch of Health100 consumer platform later in 2026), and working with regulators (CMS, FTC) to shape policy. Balance sheet trends improved (leverage 3.84x); management is prioritizing deleveraging while evaluating capital deployment, including share repurchase timing. Management reiterated multi-year targets (mid-teens EPS CAGR to 2028) and emphasized disciplined execution, client transparency (TrueCost), and continued focus on affordability, access, and simplification across the health care experience.